logo
Share SHARE
FONT-SIZE Plus   Neg

Panasonic Reports Delisting Schedule From NYSE - Quick Facts

Panasonic Corp. (PC) announced the delisting schedule from the New York Stock Exchange or "NYSE" and notified to the NYSE on April 1, 2013 that it will apply for voluntary delisting of its American Depositary Shares or "ADSs", in relation with its announcement on March 28, 2013 on its intention of delisting from the NYSE.

Panasonic listed its ADSs on the NYSE in December 1971 primarily to promote trading of its shares and to raise the visibility of the Panasonic brand in the U.S.

While the company believes the initial objectives of the U.S. ADS listing were mainly achieved, it judges that the continued listing on the NYSE is not economically justified, considering the fact that the trading volume of Panasonic's ADSs on the NYSE accounts for only a small fraction of the total trading volume of Panasonic's shares. Hence, Panasonic would apply for voluntary delisting of its ADSs from the NYSE and for termination of registration of its ADSs with SEC under the Exchange Act.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Snack and beverage giant Pepsico Inc. reported Thursday significantly higher profit in its third quarter, reflecting the absence of last year's hefty Venezuelan impairment charges, despite weak revenues. Core earnings and revenues beat market estimates. Further, the company lifted its fiscal 2016 forecast on its performance and outlook for the fourth quarter. Almost 71 percent of Americans say they don't save enough for their retirement, while around 54 percent believe they will never pay off their debt fully, according to a new national survey. The latest survey, commissioned by Experian together with Get Rich Slowly and other top U.S. personal finance... The biotech space is not for the faint hearted, given the ebbs and flows in terms of the returns from investing in it. However, for one who perseveres and astutely devises strategies with full cognizance of key regulatory events coming up, the probability of drug candidates getting FDA's blessings and sympathy plays in the space, it provides a sea of opportunity and huge upside prospects.
comments powered by Disqus
Follow RTT